4564.T Stock Drops 8.7% on May 11, 2026 as OncoTherapy Science Faces Headwinds

OncoTherapy Science, Inc. (4564.T) traded lower on the JPX today, closing at ¥21.0 after a sharp 8.7% decline. The Kawasaki-based biotech company saw volume surge to 175.9 million shares, nearly double its average. This weakness reflects broader concerns about the company’s profitability and clinical pipeline progress. With a market cap of ¥8.2 billion and negative earnings per share of -¥2.83, 4564.T stock faces significant headwinds. Investors are watching closely as the company develops cancer therapies and peptide vaccines in early-stage trials.

4564.T Stock Price Action and Trading Volume

OncoTherapy Science opened at ¥23.0 but quickly retreated to close at ¥21.0, marking a ¥2.0 loss from the previous close. The intraday range stretched from ¥20.0 to ¥24.0, showing volatility typical of small-cap biotech stocks. Trading volume exploded to 175.9 million shares, representing a 1.78x relative volume spike compared to the 96.4 million average. This elevated activity suggests institutional repositioning or profit-taking after recent gains.

The 52-week range reveals deeper concerns. 4564.T stock touched a high of ¥35.0 but has since fallen to a low of ¥19.0, indicating a 46% decline from peak levels. The 50-day moving average sits at ¥23.34, while the 200-day average stands at ¥23.68, suggesting the stock trades below intermediate support levels. Technical weakness combined with fundamental challenges creates a challenging environment for shareholders.

Financial Metrics and Valuation Concerns

4564.T stock trades at a price-to-book ratio of 4.05, well above the healthcare sector average of 2.14. The price-to-sales ratio of 10.52 also exceeds sector norms, indicating investors pay a premium despite weak profitability. Most concerning is the negative earnings yield of -0.10%, reflecting the company’s ongoing losses. With an EPS of -¥2.83 and a negative PE ratio, traditional valuation metrics offer little comfort.

The company maintains a strong balance sheet with a current ratio of 8.51, indicating ample liquidity to fund operations. Cash per share stands at ¥6.06, providing a cushion for clinical development costs. However, the company burns cash without generating positive returns on assets (-35.5%) or equity (-63%). Research and development consumes 65.8% of revenue, typical for biotech firms but unsustainable without revenue growth. Track 4564.T on Meyka for real-time updates on financial developments.

Clinical Pipeline and Growth Prospects

OncoTherapy Science develops multiple cancer therapies across different stages. OTS167, a maternal embryonic leucine zipper kinase inhibitor, advances in Phase I/II trials for acute myeloid leukemia and Phase I trials for breast cancer. OTS964, targeting T-LAK cell-originated protein kinase, addresses various cancer diseases. These small-molecule drugs represent the company’s core focus.

The peptide vaccine portfolio shows promise with S-588410 in Phase III trials for esophageal cancer and Phase II for bladder cancer. S-488210 progresses in Phase I/II for head and neck cancer, while S-588210 enters Phase I for solid tumors. Additionally, the company develops antibody drugs including OTSA101 for synovial sarcoma and KHK6640 for Alzheimer’s disease. Despite this robust pipeline, clinical trial delays or failures could pressure 4564.T stock further.

Market Sentiment and Technical Indicators

Technical analysis reveals mixed signals for 4564.T stock. The Relative Strength Index (RSI) at 48.81 suggests neutral momentum, neither overbought nor oversold. However, the MACD histogram shows -0.49, indicating bearish momentum divergence. The Average True Range (ATR) of 2.48 reflects elevated volatility typical of biotech names.

The Stochastic oscillator (%K: 11.11, %D: 12.04) signals oversold conditions, potentially attractive for contrarian traders. Williams %R at -83.33 also suggests extreme weakness. Bollinger Bands place the stock near the lower band at ¥21.33, indicating downside exhaustion. The ADX at 39.67 confirms a strong downtrend. These technical signals suggest 4564.T stock may find support near ¥20.0, though fundamental recovery remains uncertain.

Final Thoughts

OncoTherapy Science (4564.T) faces a challenging environment as the stock declined 8.7% to ¥21.0 on May 11, 2026. The biotech company’s negative earnings, high valuation multiples, and clinical trial risks create headwinds for investors. While the balance sheet remains solid and the pipeline shows potential, profitability remains distant. The stock’s technical weakness and elevated trading volume suggest further consolidation ahead. Investors should monitor clinical trial announcements closely, as positive data could reverse the downtrend. For now, 4564.T stock remains a speculative play suitable only for risk-tolerant portfolios with a long-term horizon.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.